Compounds and methods for the treatment of cancer

Details Compounds and methods for the treatment of cancer Compounds and methods for the treatment of cancer

2007-08-28

2007-08-28

Padmanabhan, Sreeni (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S274000

Reexamination Certificate

active

10646980

ABSTRACT:
(−)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (−)-OddC) or its derivative and its use to treat cancer in animals, including humans.

REFERENCES:
patent: 4000137 (1976-12-01), Dvonoch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), De Cleroq et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5466806 (1995-11-01), Belleau et al.
patent: 0 206 497 (1986-12-01), None
patent: 0 217 580 (1987-04-01), None
patent: 0 337 713 (1989-10-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 375 329 (1990-06-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0 433 898 (1990-12-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: 0 515 157 (1992-11-01), None
patent: 0 526 253 (1993-02-01), None
patent: 88/07532 (1988-10-01), None
patent: 90/12023 (1990-10-01), None
patent: 91/11186 (1991-08-01), None
patent: 91/17159 (1991-11-01), None
patent: 92/10496 (1992-06-01), None
patent: 92/10497 (1992-06-01), None
patent: 92/14729 (1992-09-01), None
patent: 92/14743 (1992-09-01), None
patent: 92/15308 (1992-09-01), None
patent: 92/18517 (1992-10-01), None
patent: 92/21676 (1992-10-01), None
patent: 94/14456 (1994-07-01), None
patent: 94/27616 (1994-12-01), None
patent: 95/18137 (1995-07-01), None
patent: 95/20595 (1995-08-01), None
patent: 95/21183 (1995-08-01), None
Brown, T. L. et al. Chemistry: The Central Science, 6th Ed., Prentice Hall: Englewood Cliffs, NJ, 1994, 373-381 and 459-461.
Dvonch, W. et al. Cancer Res. 1966, 26, pp. 2386-2389.
Francklyn, C. et al. RNA, 2002, 8, pp. 1363-3372.
Goodman & Gilman's Pharmacological Basis of Therapeutics, 9th Ed. McGraw-Hill: New York, 1996, table of contents and pp. 521-555 (Chapter 23, Reisine, T. et al. “Opioid Analgesics and Antagonists”).
Kick, E. et al. Chemistry & Biology 1997, 4(4), 297-307.
Nagase, H. et al. Life Sciences 2001, 68, 2227-2231.
http://www.nlm.nih.gov/medlineplus/mplusdictionary.html, Merriam Webster, MedlinePlus Medical Dictionary, accessed Sep. 12, 2005.
Ball, C.R., “Transplantable Colon Tumors as Chemotherapy Screening Models”,Cancer(Phila.) 36:2437-2440 (1975).
Balzarini, J. et al., “Potent and Selective Anti-HTLV-III/LAV Activity of 2',3'-Dideoxycytidinene . . . ”Biochem. Biophys. Res. Commun. 140(2):735-742 (1986).
Beach, J.W., et al., “Synthesis of Enantiomerically Pure (2'R,5'S)—(-)-1+[2-(hydroxymethyl)oathiolan-5-71]Cytosine . . . ”J. Org. Chem. 57:2217-2219 (1992).
Belleau, B., et al., “Design and Activity of a Novel Class of Nucleoside Analogs . . . ”Int. Conf. On AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Bouffard, D.Y., et al., “Kinetic Studies on 2',2'-Difluorodeoxycytidine (gemcitibine) . . . ”Biochem. Pharmacol. 45:1857-1861 (1993).
Carter, et al., “Activities of (-)-Carbovir and 3'-Azido-3'-Deoxythymidine Against . . . ”Antimicrobial Agents and Chemotherapy, 36(6):1297-1300 (1990).
Chang, C-N., et al., “Biochemical Pharmacology of (+) and (-)-2',3'-Dideoxy-3'-thioacytidine as Anti-Hepatitis B Virus Agents”J. Biol. Chem. 267:22414-22420 (1992).
Chang, Chein-Neng et al., “Deoxycytidine Deaminase-Resistant Stereoisomer . . . ”J. Biol. Chem., 357(20):13938-13942 (1992).
Chang, Chungming, et al., “Production of Hepatitis B Virus in vitro by Transient Expression . . . ”The EMBO J. 6(3):675-680 (1987).
Chen, Chin-Ho, et al., “Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells . . . ”J. Biol. Chem. 265 (20):11934-11937 (1989).
Cheng, Y.C., et al., “Human Deoxycytidine Kinase Purification and Characterization . . . ”Biochim. Biophys. Acta481:481-492 (1977).
Chottiner, E.G., “Cloning and Expression of Human Deoxycytidine Kinase cDNA”Proc. Natl. Acad. Sci, USA, 88:1531-1535 (1991).
Chu, C.K., et al., “An Efficient Total Synthesis of 3'-Azido-3'-Deoxythymidine (AZT) and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) . . . ”Tetrahedron Lett. 5349 (1988).
Chu, et al., “Comparative Activity of 2',3'-Saturated and Unsaturated Pyrimidine and Purine Nucleosides . . . ”Biochem. Pharm. 37(19):3543-3548 (1988).
Chu, et al., “Structure-Activity Relationships of Pyrimidine Nucleosides as Antiviral Agents . . . ”J. Med. Chem. 32:612 (1989).
Chu, C.K. et al., “2'-Fluoro-5-Methyl-β-L-Arabinofuranosyluridine (L-FMAU) as a Novel Antiviral Agent for Hepatitis B . . . ”Antimicrob. Agents Chemother.
Coates, J. et al., “The Separated Enantiomers of 2'-deoxy-3'-thiacytidine (BCH-189) . . . ”Antimicrob. Agents Chemother. 36:202-205 (1992).
Cretton, E., et al., “Catabolism of 3'-Azido-3'-Deoxythymidine in Hepatocytes and Liver Microsomes . . . ”Molecular Pharmacology39:258-255 (1991).
Cretton, E., et al., “Pharmokinetics of 3'-Azido-3'-Deoxythymidine . . . ”Antimicrobial Agents and Chemotherapy35(5):801-807 (1991).
Di Bisceglie, Adrian M., Rutsgi, Vinod K. et al., “Hepatocellular Carcinoma” NIH Conference,Annals of Internal Medicine108:390-401 (1988).
Di Marco, M.P. et al. “High-Performance Liquid Chromatographic Determination of the Isomeric Purity of a Series of Dioxolane Nucleoside Analogs”J. Chromatogr. 645:107-114 (1993).
Doong, Shin-Lian., et al., “Inhibition of the Replication of Hepatitis B Virus in vitro . . . ”Proc. Natl. Acad. Sci. USA88:8495-8499 (1991).
Evans, David A., et al., “New Procedure for the Direct Generation of Titanium Enolates . . . ”J. Am. Chem. Soc., 112:8215-8216 (1990).
Finlay, G. J., et al., “A Semiautomated Microculture Method for Investigating Exponentially Growing Carcinoma Cells” Anal. Biochem., 139:272-277 (1984).
Furman, et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities and Anabolic Profiles . . . ”Antimicrob. Agents and Chemother., 36(12):2686-3692 (1992).
Ganem, Don et al., “The Molecular Biology of the Hepatitis B Viruses”Ann. Rev. Biochem., 56:651-693 (1987).
Gosselin, G., “Enantiomeric 2', 3'-Deoxycytidine Derivatives are Potent Human Immunodeficiency Virus Inhibitors in Cell Culture”C. R. Acad. Sci. Paris Sci. Vie317:85-89 (1994).
Jeong, L., et al., “Asymmetric Synthesis and Biological Evaluation of β-L-(2R,5S)- and a-L-1(2R,5R)-1,3-Oxathiolane-Pyrimidine and -Purine Nucleosides and Potential Anti-HIV Agents”J. Med. Chem., 36: (1993).
Kassianides, Chris, et al., “Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine”Gastroenterology33:6899-6902 (1992).
Kim, H. O., et al., “Potent Anti-HIV and Anti-HBV Activities of (-)-L-β-Dioxolane-C . . . ”Tetrahedron Lett., 33:6899-6902 (1992).
Kim, H.O., et al., “L- β-(2S,4S)-and L-α-(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents . . . ”J. Med. Chem. 36:519-528 (1993).
Kim, H.O., et al., “13-Dioxolanylpurine Nucleosides (2R.4R) and (2R,4S) with Selective Anti-HIV-1 Activity . . . ”J. Med. Chem. 36:30-37 (1993).
Krenistsky, T.A. et al., “3'-Amino-2',

Affiliated with

Also associated with

Rating

Compounds and methods for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3899101